Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Marinus (MRNS) and Gritstone Oncology (GRTS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM – Research Report), Marinus (MRNS – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments.

Neuronetics (STIM)

JMP Securities analyst Daniel Stauder reiterated a Buy rating on Neuronetics today and set a price target of $7.00. The company’s shares closed last Tuesday at $3.22.

According to TipRanks.com, Stauder is a 3-star analyst with an average return of 16.0% and a 85.7% success rate. Stauder covers the Healthcare sector, focusing on stocks such as Lemaitre Vascular, Avanos Medical, and Atricure.

Currently, the analyst consensus on Neuronetics is a Moderate Buy with an average price target of $6.50.

See Insiders’ Hot Stocks on TipRanks >>

Marinus (MRNS)

JMP Securities analyst Jason Butler reiterated a Buy rating on Marinus today and set a price target of $15.00. The company’s shares closed last Tuesday at $9.24.

According to TipRanks.com, Butler is a 1-star analyst with an average return of -1.5% and a 39.3% success rate. Butler covers the Healthcare sector, focusing on stocks such as Vigil Neuroscience Inc, ACADIA Pharmaceuticals, and Viridian Therapeutics.

Marinus has an analyst consensus of Strong Buy, with a price target consensus of $21.60, which is a 125.9% upside from current levels. In a report issued on February 26, RBC Capital also maintained a Buy rating on the stock with a $24.00 price target.

Gritstone Oncology (GRTS)

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Gritstone Oncology today and set a price target of $4.00. The company’s shares closed last Tuesday at $2.04.

According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of -24.6% and a 30.2% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as AN2 Therapeutics, Inc., Inovio Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gritstone Oncology with a $9.40 average price target, a 351.9% upside from current levels. In a report issued on February 29, BTIG also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on STIM:

• Neuronetics Inc Shares New Investor Insights Online
• Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
• Is STIM a Buy, Before Earnings?
• Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
• Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System